The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Emerging treatment options for refractory immune thrombocytopenia
Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses emerging treatment options for refractory immune thrombocytopenia (ITP). For those patients who do not respond to all current treatment options, there are several new therapies in development. The Fc receptor inhibitor efgartigimod has been efficacious in IV formulations, and the BTK inhibitor rilzabrutinib is expected to produce positive results following the completion of the Phase III LUNA3 trial (NCT04562766). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
